Comparison of the Efficacy of Different Treatment Regimens of Ranibi-zumab in the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion
Objective To observe the clinical effects of different treatment regimens of ranibizumab in the treatment of macular edema secondary to branch retinal vein occlusion.Methods 60 cases(60 eyes)of macular edema associated with branch retinal vein occlusion from July 2020 to January 2022 admitted to the Nanxishan Hospital of Guangxi Zhuang Autonomous Region were selected as the study objects.They were divided into two groups using the random-ized numeric table method.1+Prore Nata(PRN)group:ranibizumab was given as an initial vitreous injection and then changed to an on-demand injection.3+RPN group:ranibizumab was injected intravitreal initially 3 times,once a month,and then changed to as-needed injection after 3 consecutive months of sub-loading treatment.The changes in best-corrected visual acuity and retinal thickness in the macular center recess at 1,3,6 and 12 months after the first injection were observed in the two groups,as well as the differences in the mean number of injections and the recur-rence rate of macular edema in the two groups over 1 year.Results The differences in the levels of best-corrected vi-sual acuity and macular center recess retinal thickness before treatment and at 1,3,6,and 12 months after treatment between the two groups were not statistically significant(all P>0.05).Within 1 year,the mean number of ranibizumab injections in the 1+PRN group was significantly less than that in the 3+PRN group,and the difference was statistically significant(t=4.017,P<0.001).Within 1 year,the recurrence rate was lower of the 3+PRN group than that of the 1+ PRN group,but the difference was not statistically significant(P>0.05).Conclusion Compared with the 1+PRN regi-men,the 3+PRN regimen did not lead to better functional outcomes or lower treatment needs in clinical applications.
NETL
NSTL
万方数据
